In addition, PRMT1 promoted asymmetric di-methylation of CaMKII at R9 and R275 sites, thus hindered the activation of CaMKII and protected against cardiac hypertrophy and heart failure [21]. Here, PRMT1 is linked to cardiac hypertrophy.